Better Health for All

MaxCyte's core business provides platform technologies for cell and gene therapies, targeting genetic diseases, solid tumors, infectious diseases, hematological malignancies, and autoimmune diseases.

Its technology supports 19 clinical and commercial therapies, including 4 approved cell and gene therapies like CASGEVY® for Sickle Cell Disease and Beta-Thalassemia, which received multiple regulatory approvals in 2023-2024. The company's platform has been validated in over 70 clinical trials. MaxCyte has no revenue from products with negative health outcomes. The company's Code of Conduct and Ethics outlines a commitment to environmentally responsible business practices and a substance abuse policy. MaxCyte's SeQure™ services deliver assays to detect on- and off-target effects in gene editing. The company's Code of Conduct and Ethics states that employees should ensure financial disclosure is accurate and transparent, enabling investors to assess business risks. MaxCyte offers SeQure DX™ gene editing risk assessment services. The company has implemented a Code of Conduct awareness, training, and review program, with a Compliance Officer responsible for training. MaxCyte's collaborative approach has supported over 70 clinical trials across diverse indications, and a CMC amendment for a clinical trial was approved by the FDA.

Fair Money & Economic Opportunity

MaxCyte, Inc. is a global cell-engineering company that provides platform technologies for cell-based research, development, and commercialization of cell therapies.

The company generates revenue through sales of instruments, consumables, and strategic partnerships and licensing agreements. The provided articles consistently describe MaxCyte's business as related to biotechnology, biopharma, and life sciences. There is no evidence in any of the articles to suggest that MaxCyte, Inc. operates as a financial institution or offers any lending, deposit, or other financial services to consumers or businesses. Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to the company's core business model.

Fair Pay & Worker Respect

MaxCyte provides comprehensive medical, dental, and vision insurance, including a "No Cost" option for employees and their families.

The company has maintained a low voluntary employee turnover rate, which has been between 5.5% and 7% during each of the past four years, with a 2023 goal to keep it at or below 10%.

Honest & Fair Business

MaxCyte's corporate governance documents reference the existence of a whistleblower policy.

However, the articles provide no specific details regarding its strength, scope, training, effectiveness, or any quantitative metrics that would allow for a score to be assigned based on the rubric's defined tiers. For all other KPIs, including regulatory fines, transparency indices, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, anti-corruption policies, and third-party verification, the provided articles explicitly state that no relevant quantitative data is available.

No War, No Weapons

The provided articles do not contain any specific, concrete data points or explicit statements regarding MaxCyte, Inc.'s involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any related policies and oversight.

While some articles mention the company's technology and general ESG oversight, there is no direct evidence to score any of the KPIs under the 'No War, No Weapons' value.

Planet-Friendly Business

No specific, concrete data points were provided in the article to assess MaxCyte, Inc. against any of the Planet-Friendly Business KPIs.

The article explicitly states 'No data provided' for all environmental metrics, including greenhouse gas emissions, renewable energy usage, water consumption, waste diversion, and climate-related targets or initiatives.

Respect for Cultures & Communities

The provided articles discuss MaxCyte's general ESG strategy, including establishing board-level oversight and executive-level management of ESG, and express a commitment to diversity, inclusion, and ethical behavior.

However, neither article provides any specific quantitative data, numbers, or percentages related to the defined KPIs for 'Respect for Cultures & Communities'. There is no evidence regarding formal partnerships, revenue reinvestment in local communities, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, FPIC participation, community governance, cultural preservation investments, local procurement, indigenous supplier engagement, cultural site protection, social license, charitable giving, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion. Therefore, no KPIs can be scored based on the evidence provided.

Safe & Smart Tech

MaxCyte's 2024 10-K filing reported no data breaches, indicating a clean record for at least the past three years.

The company's privacy policy states an aim to protect personal information from unauthorized access, use, disclosure, alteration, or destruction, and no incidents of unauthorized data use are documented. Users are granted rights to access, update, or remove their information, opt-out of marketing communications, and for individuals in the EEA, rights to receive/transfer data, limit/restrict use, and withdraw consent. MaxCyte states its commitment to complying with applicable legal obligations, including data protection laws outside the United States, and has adopted a Code of Conduct and Ethics. The Audit Committee oversees cybersecurity risk management, meeting twice annually with relevant IT and business personnel.

Zero Waste & Sustainable Products

MaxCyte Inc.'s 2023 ESG Summary Report indicates no regulatory actions, violations, fines, or compliance issues related to waste disposal were mentioned.

For all other KPIs, the provided articles explicitly state a lack of specific quantitative data for MaxCyte, Inc. Information regarding EU regulations and targets pertains to the general regulatory environment and not the company's specific performance.